As a tumor-associated antigen, EphA2 has been extensively studied over the past 25 years, establishing its status as a promising molecular target for therapeutic development and clinical translation in NSCLC and other cancers (16–18). Here, EPHA2 is linked to non-small cell lung carcinoma.